Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility
June 14, 2022 08:05 ET | Avid Bioservices, Inc
AD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility Build-Out of Facility’s CGMP Manufacturing Suites Continues, Expected to Come Online in...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Announces Further Expansion of Process Development Capacity for Mammalian Cell Business
June 13, 2022 08:05 ET | Avid Bioservices, Inc
New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity Expansion to Cost...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum
March 16, 2022 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2022 after Market Close on March 8, 2022
March 01, 2022 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Announces Official Opening of Second Downstream Processing Suite Within Myford North Facility
January 10, 2022 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments
December 07, 2021 16:05 ET | Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $26.1 Million -- -- Initiated Strategic Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy -- -- Signed $36 Million in...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer
October 07, 2021 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments
September 08, 2021 16:05 ET | Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- --  Signed $23 Million in New Business Orders and Ended the Quarter...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices to Participate at Upcoming Investor Conferences
September 02, 2021 16:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices logo_no tag_RGB.jpg
Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors
July 01, 2021 08:05 ET | Avid Bioservices, Inc
TUSTIN, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...